447 related articles for article (PubMed ID: 22167180)
1. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
[TBL] [Abstract][Full Text] [Related]
3. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.
Falkowska E; Ramos A; Feng Y; Zhou T; Moquin S; Walker LM; Wu X; Seaman MS; Wrin T; Kwong PD; Wyatt RT; Mascola JR; Poignard P; Burton DR
J Virol; 2012 Apr; 86(8):4394-403. PubMed ID: 22345481
[TBL] [Abstract][Full Text] [Related]
4. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
[TBL] [Abstract][Full Text] [Related]
5. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
6. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.
Yasmeen A; Ringe R; Derking R; Cupo A; Julien JP; Burton DR; Ward AB; Wilson IA; Sanders RW; Moore JP; Klasse PJ
Retrovirology; 2014 May; 11():41. PubMed ID: 24884783
[TBL] [Abstract][Full Text] [Related]
7. Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.
Heyndrickx L; Stewart-Jones G; Jansson M; Schuitemaker H; Bowles E; Buonaguro L; Grevstad B; Vinner L; Vereecken K; Parker J; Ramaswamy M; Biswas P; Vanham G; Scarlatti G; Fomsgaard A;
PLoS One; 2013; 8(9):e74552. PubMed ID: 24023951
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
[TBL] [Abstract][Full Text] [Related]
9. CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
Gardner MR; Fellinger CH; Prasad NR; Zhou AS; Kondur HR; Joshi VR; Quinlan BD; Farzan M
J Virol; 2016 Sep; 90(17):7822-32. PubMed ID: 27334589
[TBL] [Abstract][Full Text] [Related]
10. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.
Tolbert WD; Nguyen DN; Tehrani ZR; Sajadi MM; Pazgier M
mBio; 2021 Aug; 12(4):e0127421. PubMed ID: 34281393
[TBL] [Abstract][Full Text] [Related]
11. Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.
Kesavardhana S; Das R; Citron M; Datta R; Ecto L; Srilatha NS; DiStefano D; Swoyer R; Joyce JG; Dutta S; LaBranche CC; Montefiori DC; Flynn JA; Varadarajan R
J Biol Chem; 2017 Jan; 292(1):278-291. PubMed ID: 27879316
[TBL] [Abstract][Full Text] [Related]
12. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
[TBL] [Abstract][Full Text] [Related]
13. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice.
Galkin A; Chen Y; Guenaga J; O'Dell S; Acevedo R; Steinhardt JJ; Wang Y; Wilson R; Chiang CI; Doria-Rose N; Grishaev AV; Mascola JR; Li Y
J Immunol; 2020 Mar; 204(6):1543-1561. PubMed ID: 32066595
[TBL] [Abstract][Full Text] [Related]
15. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
[TBL] [Abstract][Full Text] [Related]
16. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
Utachee P; Isarangkura-na-ayuthaya P; Tokunaga K; Ikuta K; Takeda N; Kameoka M
Retrovirology; 2014 Apr; 11():32. PubMed ID: 24758333
[TBL] [Abstract][Full Text] [Related]
17. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates.
Douagi I; Forsell MN; Sundling C; O'Dell S; Feng Y; Dosenovic P; Li Y; Seder R; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
J Virol; 2010 Feb; 84(4):1683-95. PubMed ID: 19955308
[TBL] [Abstract][Full Text] [Related]
18. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign.
Tran K; Poulsen C; Guenaga J; de Val N; Wilson R; Sundling C; Li Y; Stanfield RL; Wilson IA; Ward AB; Karlsson Hedestam GB; Wyatt RT
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):E738-47. PubMed ID: 24550318
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
Zhang MY; Yuan T; Li J; Rosa Borges A; Watkins JD; Guenaga J; Yang Z; Wang Y; Wilson R; Li Y; Polonis VR; Pincus SH; Ruprecht RM; Dimitrov DS
PLoS One; 2012; 7(9):e44241. PubMed ID: 22970187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
